LONDON (Alliance News) - Reagents developer Avacta Group PLC on Wednesday appointed Jose Saro as chief medical officer to lead the firm's therapeutic development strategy.
Saro brings over 20 years of experience in the pre-clinical, translational and early clinical development of oncology assets, the company explained.
Saro joins Avacta from Roche Holding AG, where he held the role of senior translational medicine leader focusing on immuno-oncology and the development of combination products.
Prior to his role at Roche, Saro was executive director of oncology global development and medical affairs at Bristol Myers Squibb Co.
Avacta shares were trading down 3.9% at 27.86 pence.
Avacta Group (AVCT)
Roche Holding P (0QOK)